Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

BENJAMIN LEVY

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1346276326
CMS profile
197297
Location
BALTIMORE, MD

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$99,858.11

74 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
Merck Sharp & Dohme LLC $31,986.80 18
AstraZeneca Pharmaceuticals LP $15,643.77 9
Daiichi Sankyo Inc. $13,549.18 13
PFIZER INC. $10,061.87 7
Gilead Sciences, Inc. $9,124.09 6
Novocure Inc. $4,843.87 11
Genentech USA, Inc. $3,288.53 5
Janssen Global Services, LLC $2,700.00 1
AstraZeneca UK Limited $2,660.00 1
Roche Diagnostics Corporation $2,604.00 1
Boehringer Ingelheim Pharmaceuticals, Inc. $2,220.00 1
GENZYME CORPORATION $1,176.00 1

Page 2 of 2; records 51–74 of 74 matching records. This page contains 24 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

BENJAMIN LEVY

NPI 1346276326 · CMS profile ID 197297

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

BALTIMORE, MD

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–74 of 74 matching records. This page contains 24 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1346276326?year=2023&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
BENJAMIN LEVY, NPI 1346276326, CMS profile ID 197297. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–74 of 74 matching records. This page contains 24 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1346276326?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). BENJAMIN LEVY, NPI 1346276326, CMS profile ID 197297. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–74 of 74 matching records. This page contains 24 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1346276326?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
BENJAMIN LEVY, NPI 1346276326, CMS profile ID 197297, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–74 of 74 matching records. This page contains 24 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1346276326?year=2023&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

74 matching records · $99,858.11 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 74 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–74 of 74.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AstraZeneca UK Limited $2,660.0004/14/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1017016161 CMS
AstraZeneca Pharmaceuticals LP $1,995.0004/06/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015622199 CMS
AstraZeneca Pharmaceuticals LP $53.3004/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015625527 CMS
AstraZeneca Pharmaceuticals LP $33.3004/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015645437 CMS
PFIZER INC. $3,670.0003/31/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049546561 CMS
PFIZER INC. $122.0703/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049667787 CMS
Daiichi Sankyo Inc. $1,935.0003/29/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1006531787 CMS
Merck Sharp & Dohme LLC $150.0003/27/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048584657 CMS
Merck Sharp & Dohme LLC $7,930.0003/27/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048584661 CMS
AstraZeneca Pharmaceuticals LP $2,660.0003/17/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012043833 CMS
Merck Sharp & Dohme LLC $239.5503/17/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048254079 CMS
Merck Sharp & Dohme LLC $58.1903/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048635261 CMS
Merck Sharp & Dohme LLC $64.9903/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048635265 CMS
Merck Sharp & Dohme LLC $64.9903/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048635273 CMS
Merck Sharp & Dohme LLC $63.4803/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048635277 CMS
Merck Sharp & Dohme LLC $239.5503/16/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048254139 CMS
Merck Sharp & Dohme LLC $125.9003/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048635269 CMS
Merck Sharp & Dohme LLC $31.7403/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048635595 CMS
PFIZER INC. $533.4803/09/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049667889 CMS
AstraZeneca Pharmaceuticals LP $95.9202/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014469117 CMS
Daiichi Sankyo Inc. $47.6502/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1006391789 CMS
Genentech USA, Inc. $138.3602/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040311013 CMS
Genentech USA, Inc. $2,910.0002/22/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040311031 CMS
Genentech USA, Inc. $146.1102/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040311037 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $169,986.22 69
PY2020 $79,206.68 42
PY2021 $84,167.25 32
PY2022 $77,728.34 43
PY2023 $99,858.11 74
PY2024 $53,293.31 41
PY2025 $14,177.65 20

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $220,608.83 7
PY2024 Principal investigator $180,397.84 6
PY2023 Recipient $13,291.75 2
PY2023 Principal investigator $218,031.91 4
PY2022 Principal investigator $333,960.55 5
PY2021 Principal investigator $314,003.53 9
PY2020 Principal investigator $275,043.12 3
PY2019 Principal investigator $36,904.00 2

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

7 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $533.81 12/31/2025 Non-covered Recipient Entity
Sibley Memorial Hospital
A Phase 2a Study with Safety Run-in to Evaluate the Safety, Tolerability, and Preliminary Efficacy of FF-10832 Monotherapy or in Combination with Pembrolizumab in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1232935823
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $81,860.85 08/31/2025 Non-covered Recipient Entity
Johns Hopkins University Student Health And Wellness Center
Zongertinib Out of Scope / Named Patient Use requests No dispute reported 06/30/2026 1220995208
Principal investigator 1 Eli Lilly and Company $39,133.00 08/28/2025 Non-covered Recipient Entity
JOHNS HOPKINS UNIVERSITY
A PHASE 1/2 STUDY OF ORAL SELPERCATINIB (LOXO-292) IN PATIENTS WITH ADVANCED SOLID TUMORS, INCLUDING RET FUSION-POSITIVE SOLID TUMORS, MEDULLARY THYROID CANCER, AND OTHER TUMORS WITH RET ACTIVATION (LIBRETTO-001) No dispute reported 06/30/2026 1187885532
Principal investigator 1 AstraZeneca Pharmaceuticals LP $24,983.81 06/27/2025 Non-covered Recipient Entity
JOHNS HOPKINS UNIVERSITY
A Phase II Study Assessing the Efficacy of Osimertinib in Combination with Savolitinib in Patients with EGFRm+ and MET+ Locally Advanced or Metastatic Non-Small Cell Lung Cancer who have Progressed Following Treatment with Osimertinib No dispute reported 06/30/2026 1185538713
Principal investigator 1 AstraZeneca Pharmaceuticals LP $412.42 06/18/2025 Non-covered Recipient Entity
JOHNS HOPKINS MEDICINE
A Phase II Study Assessing the Efficacy of Osimertinib in Combination with Savolitinib in Patients with EGFRm+ and MET+ Locally Advanced or Metastatic Non-Small Cell Lung Cancer who have Progressed Following Treatment with Osimertinib No dispute reported 06/30/2026 1185538709
Principal investigator 1 AstraZeneca Pharmaceuticals LP $35,649.81 05/30/2025 Non-covered Recipient Entity
JOHNS HOPKINS UNIVERSITY
This is a Phase III, randomised, double-blind, placebo-controlled, multicentre, international study assessing the efficacy and safety of durvalumab MEDI4736 and domvanalimab AB154 compared with durvalumab plus placebo in adults with locally advanced Stage III No dispute reported 06/30/2026 1185538715
Principal investigator 1 AstraZeneca Pharmaceuticals LP $38,035.13 03/28/2025 Non-covered Recipient Entity
JOHNS HOPKINS TECHNOLOGY VENTURES
This is a Phase III, randomised, double-blind, placebo-controlled, multicentre, international study assessing the efficacy and safety of durvalumab MEDI4736 and domvanalimab AB154 compared with durvalumab plus placebo in adults with locally advanced Stage III No dispute reported 06/30/2026 1185538711